1
|
Guo H, Lin H. The value of multimodal treatment in anaplastic thyroid cancer patients with distant metastasis. BMC Surg 2024; 24:79. [PMID: 38438944 PMCID: PMC10913613 DOI: 10.1186/s12893-024-02375-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/25/2023] [Accepted: 02/27/2024] [Indexed: 03/06/2024] Open
Abstract
BACKGROUND Anaplastic thyroid cancer (ATC) is a rare and aggressive malignancy with a poor prognosis, particularly in patients presenting with distant metastasis (DM). This study aimed to assess the effect of combination treatment strategies on survival in ATC patients with DM. METHODS A retrospective analysis was conducted using data from the Surveillance, Epidemiology, and End Results (SEER) database to identify primary ATC cases with DM at diagnosis. Univariate and multivariate Cox proportional hazards regression analyses were performed to identify independent risk factors for survival. RESULTS Of the 315 ATC patients with DM included in the study, surgery to the primary tumor, radiotherapy, chemotherapy, and lung metastasis were identified as independent risk factors for survival. Patients who received primary tumor surgery plus chemotherapy or surgery plus chemoradiation exhibited a superior outcome compared to those who received only one treatment modality. CONCLUSION Our findings suggest that a combination treatment approach, particularly surgery combined with radiotherapy or surgery combined with chemoradiotherapy, may provide the most optimal treatment option for ATC patients with DM. These results may provide some evidence for clinical decision making, but larger sample cohorts are still needed for validation.
Collapse
Affiliation(s)
- Hongen Guo
- Department of Dermatology, Dermatology Hospital of Fuzhou, Fuzhou, Fujian Province, PR China
| | - Hanqing Lin
- Department of Otolaryngology, The First Affiliated Hospital of Fujian Medical University, No. 20 Chazhong Road, Fuzhou, 350005, Fujian Province, PR China.
| |
Collapse
|
2
|
Cleere EF, Crotty TJ, Hintze JM, Fitzgerald CWR, Kinsella J, Lennon P, Timon CVI, Woods RSR, Shine NP, O'Neill JP. The role of surgery for anaplastic thyroid carcinoma in the era of targeted therapeutics: A scoping review. Laryngoscope Investig Otolaryngol 2023; 8:1673-1684. [PMID: 38130255 PMCID: PMC10731486 DOI: 10.1002/lio2.1172] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2023] [Accepted: 10/06/2023] [Indexed: 12/23/2023] Open
Abstract
Background Questions exist regarding patient selection for surgery in anaplastic thyroid carcinoma (ATC), particularly with the advent of neoadjuvant-targeted therapeutics. The present scoping review sought to evaluate what extent of surgical resection should be performed in ATC. Methods A scoping review was carried out in accordance with Joanna Briggs Institute and the preferred reporting items for systematic reviews and meta-analyses extension for scoping reviews (PRISMA-ScR) protocols. Included studies were required to provide clear description of the surgery performed for ATC. Results The final search identified 6901 articles. Ultimately only 15 articles including 1484 patients met inclusion criteria. A total of 765 patients (51.5%) underwent attempted curative intent surgery. The approach to resection of adjacent tissues varied between studies. Eight studies considered laryngeal ± pharyngeal resection (8/15, 53.3%), eight studies (53.3%) considered tracheal resection and again eight studies (53.3%) considered esophageal resection. More extensive resections increased morbidity without improving overall survival (OS) (<9 months in the 12 studies using a combination of surgery and chemoradiotherapy). In the three studies utilizing targeted therapy in addition to surgery, OS was notably improved while surgical resection following neoadjuvant therapy was less extensive. Conclusions There is no clear agreement in the literature regarding the limits of surgical resection in locoregionally advanced ATC. A definition of surgically resectable disease will be required to guide surgical decision making in ATC, particularly with the potential to reduce tumor burden using neoadjuvant targeted treatment in suitable patients. Level of evidence III.
Collapse
Affiliation(s)
- Eoin F. Cleere
- Department of Otolaryngology Head and Neck Surgery, Beaumont HospitalDublinIreland
- The Royal College of Surgeons in IrelandDublinIreland
| | - Thomas J. Crotty
- Department of Otolaryngology Head and Neck Surgery, St James's HospitalDublinIreland
| | - Justin M. Hintze
- Department of Otolaryngology Head and Neck Surgery, St James's HospitalDublinIreland
| | | | - John Kinsella
- Department of Otolaryngology Head and Neck Surgery, St James's HospitalDublinIreland
| | - Paul Lennon
- Department of Otolaryngology Head and Neck Surgery, St James's HospitalDublinIreland
| | - Conrad V. I. Timon
- Department of Otolaryngology Head and Neck Surgery, St James's HospitalDublinIreland
| | - Robbie S. R. Woods
- Department of Otolaryngology Head and Neck Surgery, Beaumont HospitalDublinIreland
| | - Neville P. Shine
- Department of Otolaryngology Head and Neck Surgery, Beaumont HospitalDublinIreland
| | - James P. O'Neill
- Department of Otolaryngology Head and Neck Surgery, Beaumont HospitalDublinIreland
- The Royal College of Surgeons in IrelandDublinIreland
| |
Collapse
|
3
|
Ma T, Cui J, Shi P, Liang M, Song W, Zhang X, Wang L, Shi Y. Assessing the role of central lymph node ratio in predicting recurrence in N1a low-to-intermediate risk papillary thyroid carcinoma. Front Endocrinol (Lausanne) 2023; 14:1158826. [PMID: 37790606 PMCID: PMC10543417 DOI: 10.3389/fendo.2023.1158826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2023] [Accepted: 08/23/2023] [Indexed: 10/05/2023] Open
Abstract
Introduction Lymph node metastasis in patients with papillary thyroid carcinoma (PTC) is associated with postoperative recurrence. Recently, most studies have focused on the evaluation of recurrence in patients with late-stage PTC, with limited data on those with early-stage PTC. We aimed to assess the relationship between lymph node ratio (LNR) and recurrence in low-to-intermediate-risk patients and validate its diagnostic efficiency in both structural (STR) and biochemical recurrence (BIR). Methods Clinical data of patients with PTC diagnosed at the Affiliated Hospital of Jining Medical University were retrospectively collected. The optimal LNR cut-off values for disease-free survival (DFS) were determined using X-tile software. Predictors were validated using univariate and multivariate Cox regression analyses. Results LNR had a higher diagnostic effectiveness than metastatic lymph nodes in patients with low-to-intermediate recurrence risk N1a PTC. The optimal LNR cutoff values for STR and BIR were 0.75 and 0.80, respectively. Multivariate Cox regression analysis showed that LNR≥0.75 and LNR≥0.80 were independent factors for STR and BIR, respectively. The 5-year DFS was 90.5% in the high LNR (≥0.75) and 96.8% in low LNR (<0.75) groups for STR. Regarding BIR, the 5-year DFS was 75.7% in the high LNR (≥0.80) and 86.9% in low LNR (<0.80) groups. The high and low LNR survival curves exhibited significant differences on the log-rank test. Conclusion LNR was associated with recurrence in patients with low-to-intermediate recurrence risk N1a PTC. We recommend those with LNR≥0.75 require a comprehensive evaluation of lateral neck lymphadenopathy and consideration for lateral neck dissection and RAI treatment.
Collapse
Affiliation(s)
- Teng Ma
- Department of Thyroid Surgery, Affiliated Hospital of Jining Medical University, Jining, Shandong, China
- Breast Disease Center, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
| | - Jian Cui
- Breast Disease Center, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
| | - Peng Shi
- Department of Thyroid Surgery, Affiliated Hospital of Jining Medical University, Jining, Shandong, China
| | - Mei Liang
- Department of Thyroid Surgery, Affiliated Hospital of Jining Medical University, Jining, Shandong, China
| | - Wenxiao Song
- Department of Thyroid Surgery, Affiliated Hospital of Jining Medical University, Jining, Shandong, China
| | - Xueyan Zhang
- Qingdao Medical College, Qingdao University, Qingdao, Shandong, China
| | - Lulu Wang
- Department of Cardiovascular Surgery, Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
| | - Yafei Shi
- Department of Thyroid Surgery, Affiliated Hospital of Jining Medical University, Jining, Shandong, China
| |
Collapse
|
4
|
Dai Q, Fu X, Ding Y, He Q, Qiu X. Clinicopathological features and prognostic factors analysis of multiple synchronous distinct subtypes of primary thyroid carcinoma. Endocrine 2023; 79:491-501. [PMID: 36399310 DOI: 10.1007/s12020-022-03243-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2022] [Accepted: 10/22/2022] [Indexed: 11/19/2022]
Abstract
PURPOSE To investigate the clinicopathological features, diagnosis, treatment, and prognosis of multiple synchronous distinct subtypes of primary thyroid carcinomas. METHODS The clinical data of 68 cases of synchronous carcinomas of the thyroid (STC) admitted to the Department of Thyroid Surgery in our hospital from January 2013 to December 2021 were reviewed. According to the pathological type, they were divided into the Synchronous differentiated and differentiated thyroid Carcinoma (SDDTC) group (42 cases), the Synchronous medullary and differentiated thyroid Carcinoma (SMDTC) group (18 cases), and the Synchronous Anaplastic and differentiated thyroid Carcinoma (SADTC)group (8 cases). The diagnosis, treatment, and survival of patients in each group were analyzed. RESULTS Women with coexisting thyroid cancer were predominant (59 cases). Most of the symptoms were found on physical examination (47.1%) and neck mass (45.6%). The median age of patients in the SDDTC group, SADTC group, and SMDTC group was 47.5 (28-74) years old, 68.5 (26-75) years old, and 56.5 (39-74) years old. The age of the SADTC group and SMDTC group was older than that of the SDDTC group (P = 0.04, P = 0.03), and the rate of lymph node metastasis in groups SADTC (62.5%) and SMDTC (55.6%) was higher than in group SDDTC (21.4%). The disease course time, tumor location, clinical stage, and mortality of the SADTC group were significantly different from those of the SDDTC group and SMDTC group (P < 0.05). The overall survival of patients with synchronous carcinomas of the thyroid was 6-105 months, and the median overall survival was 38.5 months. The tumor-free survival was 0-90 months, 19.1% of patients developed distant metastasis, 11.8% of patients had postoperative recurrence, as well as the survival rate was estimated 91.18%. Cox model multivariate analysis showed that cervical lateral lymph node metastasis and tumor stage III/IV were independent risk factors for progression-free survival(PFS). The comparison results of the survival curves showed that the overall survival (OS)of the patients in the SADTC group was significantly worse (P < 0.01), while there was no significant difference in the PFS of different pathological types (χ2 = 5.024, P = 0.081).The OS of different treatment methods was significantly different (P = 0.002), but there was no significant difference in OS between local recurrence and distant metastases with or without surgery (χ2 = 0.954, P = 0.329). CONCLUSIONS The STC has relatively unique clinical characteristics, and most patients can get a better prognosis after radical surgery. Pathological type, lateral cervical lymph node metastasis, tumor stage, and treatment are important factors which affect the prognosis of the disease. Since there are two distinct tumors with different aggressiveness, treatment options, and prognosis, individualized management is required.
Collapse
Affiliation(s)
- Quanwei Dai
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, 1 Jian She Road, Zhengzhou, Henan, 450052, People's Republic of China
| | - Xinghao Fu
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, 1 Jian She Road, Zhengzhou, Henan, 450052, People's Republic of China
| | - Yalei Ding
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, 1 Jian She Road, Zhengzhou, Henan, 450052, People's Republic of China
| | - Qi He
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, 1 Jian She Road, Zhengzhou, Henan, 450052, People's Republic of China
| | - Xinguang Qiu
- Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, 1 Jian She Road, Zhengzhou, Henan, 450052, People's Republic of China.
| |
Collapse
|
5
|
Mustafa DH, Ahmed BS, Haweizy RM, Dewana AM. Evaluation of anaplastic thyroid carcinoma in the Kurdistan region of Iraq. BMC Surg 2022; 22:364. [PMID: 36271386 PMCID: PMC9587643 DOI: 10.1186/s12893-022-01810-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2022] [Accepted: 09/29/2022] [Indexed: 11/17/2022] Open
Abstract
Background Anaplastic thyroid carcinoma is a rare and lethal disease that accounts for 1–2% of thyroid malignancies. It is an aggressive locoregional disease with a high rate of distant metastasis, a poor prognosis, and a mean survival rate of 3–6 months after diagnosis. This retrospective study aimed to analyse the clinical and pathological features of ATC to assess treatment procedures and its outcome. Methods We analysed data from 22 patients diagnosed with ATC from 2018 to 2021, using the Kaplan-Meier method and log-rank test to determine overall survival. Results Patients’ median age was 64.3 ± 17.1 years. Females were more affected (male/female ratio: 1:1.7); 14 cases occurred in females (63.6.4%), and eight in males (36.4%). The most common manifestations were neck enlargement (81.8%) and dyspnoea (72.27%), and the tumour size was > 4 cm in 17 (77.3%) patients. The percentage of cases that presented in clinical-stage IVA was 36.4%, with 31.8% presenting in clinical-stage IVB and 31.8% presenting in clinical-stage VIB. Among 22 cases, 14 (63.6%) were operable, and 8 (36.4) were inoperable (p = 0.015). Multimodal therapies were associated with better survival (surgery plus radiotherapy without systemic treatment, P = 0.063). The median overall survival was three months (IC 95%, 0.078–5.922). One-year and two-year survival rates were 9% and 4.5%, respectively. Conclusion ATC is a rapidly growing cancer that, fortunately, is rare. Early diagnosis and multimodality treatment may provide a better quality of life and survival time for this group of patients. Supplementary Information The online version contains supplementary material available at 10.1186/s12893-022-01810-w.
Collapse
Affiliation(s)
- Dilshad Hamad Mustafa
- Department of Faciomaxillary Surgery, College of Dentistry, Hawler Medical University, Erbil, Iraq.
| | | | | | - Azhy Muhammed Dewana
- Department of Surgery, College of Medicine, Hawler Medical University, Erbil, Iraq
| |
Collapse
|
6
|
Sun XS, Le Guevelou J, Jacquemin J, Drouet Y, Sio TS, Bar-Sela G, Carrie C, Faivre JC, Khalifa J, Demiroz C, Qiu H, Schick U, Atalar B, Fakhry N, Mengue L, Pan J, Servagi-Vernat S, Thariat J. Impact of radiotherapy on survival in resected or unresectable anaplastic thyroid carcinomas, a Rare Cancer Network study. Cancer Radiother 2022; 26:717-723. [PMID: 35715353 DOI: 10.1016/j.canrad.2022.01.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2021] [Revised: 01/04/2022] [Accepted: 01/14/2022] [Indexed: 11/15/2022]
Abstract
PURPOSE Anaplastic thyroid carcinomas (ATC) are a heterogenous group of tumors of overall dismal prognosis. We designed models to identify relevant prognostic factors of survival of irradiated ATC patients including radiotherapy modalities (field size, dose). MATERIAL AND METHODS Between 2000 and 2017, 166 ATC patients' treatments were divided into surgery and postoperative radiotherapy (poRT) or definitive radiotherapy (RT). Multiple imputation approach was used for missing data. Prognostic factors were identified using Lasso-penalized Cox modelling and predicted risk scores were built. RESULTS Patients undergoing RT (n=70) had more adverse patient and disease characteristics than those undergoing poRT (n=96). Corresponding median survival rates were 5.4 and 12.1 months, respectively. PoRT patients undergoing poRT more likely received extended-field radiotherapy with prophylactic nodal irradiation, but rather received platinum- vs. adriamycin-based chemoradiotherapy. Radiotherapy was conventionally fractionated, delivered >60Gy in 51.9% and 61.7% and used extended fields in 88.5% and 71.2% of patients with poRT or RT. Radiotherapy interruption rates for toxicity were similar in the two groups. The best poRT-group model identified age>45yo, PS≥1, pathologic tumor stage≥pT4b,>N1 and R2 resection as poor prognostic factors. The best RT-group model (C-index of 0.72) identified PS≥3,>N1 and extended-field radiotherapy with prophylactic nodal irradiation (as opposed to tumour-bed irradiation only) as poor prognostic factors. CONCLUSION In patients undergoing poRT, radiotherapy parameters had little influence over their survival irrespective of patient, disease characteristics, and quality of resection. In patients undergoing RT, extended-field radiotherapy improved survival in addition to PS and nodal stage.
Collapse
Affiliation(s)
- X S Sun
- Department of Radiation Therapy, University Hospital Besancon-Montbeliard, Montbeliard, France.
| | - J Le Guevelou
- Department of Radiation Oncology, Centre François Baclesse, Caen, France
| | - J Jacquemin
- Département Prévention et Santé Publique, Centre Léon Bérard, Lyon, France
| | - Y Drouet
- Département Prévention et Santé Publique, Centre Léon Bérard, Lyon, France
| | - T S Sio
- Department of Radiation Oncology, Mayo Clinic, Phoenix, Arizona, USA
| | - G Bar-Sela
- Department of Radiation Oncology, Rambam health Care Campus, Haifa, Israel
| | - C Carrie
- Department of Radiation Oncology, Centre Leon Berard, Lyon, France
| | - J-C Faivre
- Department of Radiation Oncology, Institut de Cancérologie de Lorraine, Nancy, France
| | - J Khalifa
- Department of Radiation Oncology, Oncopole, Toulouse, France
| | - C Demiroz
- Department of Radiation Oncology, Uludag University school of medicine, Bursa, Turkey
| | - H Qiu
- Department of Radiation Oncology, University Hospital, Limoges, France
| | - U Schick
- Department of Radiation Oncology, CHRU Brest, Brest, France
| | - B Atalar
- Department of Radiation Oncology, University Hospital Acibadem MAA University, School of Medicine, Istanbul, Turkey
| | - N Fakhry
- Department of Surgery, CHU La Conception, Marseille, France
| | - L Mengue
- Department of Radiation Therapy, University Hospital Besancon-Montbeliard, Montbeliard, France
| | - J Pan
- Department of Radiation Oncology, Fujian Province Tumor Hospital, Fuzhou, China
| | - S Servagi-Vernat
- Department of Radiation Oncology, Institut Jean Godinot, Reims, France
| | - J Thariat
- Department of Radiation Oncology, Centre François Baclesse, Caen, France
| |
Collapse
|